Risultati di ricerca
Johannes (Hans) Carolus Clevers (born 27 March 1957) [3] [4] is a Dutch molecular geneticist, cell biologist and stem cell researcher. He became the Head of Pharma, Research and Early Development, and a member of the Corporate Executive Committee, of the Swiss healthcare company Roche in 2022.
Hans Clevers is Head of pharma Research and Early Development (pRED) of Roche, Basel Switzerland, since March 2022. He was group leader at the Hubrecht Institute from 2002 until March 2022 and currently he is advisor/guest researcher at the Hubrecht Institute.
Hans Clevers is a Distinguished Professor at Utrecht University and guest scientist/advisor at the Hubrecht Institute (KNAW). He is also guest scientist/advisor of the Princess Máxima Center for pediatric oncology and Oncode Investigator. Hans Clevers's stem-cell research plays a prominent role within the Utrecht strategic research theme Life ...
1997. Wnt signalling in stem cells and cancer. T Reya, H Clevers. Nature 434 (7035), 843-850. , 2005. 4739. 2005. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC−/− colon carcinoma. V Korinek, N Barker, PJ Morin, D Van Wichen, R De Weger, KW Kinzler, ...
Prof Dr Hans Clevers. Head of Pharma Research and Early Development (pRED) (Member of the enlarged CEC since 2022) Zur deutschen Version. Personal Data. Nationality Netherlands. Year of Birth 1957. Education. 1982 University of Utrecht, M.Sc. in Biology. 1984 University of Utrecht, M.D. 1985 University of Utrecht, Ph.D. Professional experience.
Hans Clevers runs a research group at the Hubrecht Institute for Developmental Biology and Stem Cell Research of the Royal Dutch Academy of Arts and Sciences. He is also the Director of...
16 feb 2023 · AN AUDIENCE WITH. 16 February 2023. Mini-organs attract big pharma. Hans Clevers, head of Pharma Research & Early Development at Roche, discusses the role for organoids in drug discovery and...
